key: cord-0977682-mslceu1r authors: Rolfo, Christian; Meshulami, Noy; Russo, Alessandro; Krammer, Florian; Garcia-Sastre, Adolfo; Mack, Philip C.; Gomez, Jorge E.; Bhardwaj, Nina; Benyounes, Amin; Sirera, Rafael; Moore, Amy; Rohs, Nicholas; Henschke, Claudia I.; Yankelevitz, David; King, Jennifer; Shyr, Yu; Bunn, Paul A.; Minna, John D.; Hirsch, Fred R. title: Lung Cancer and SARS-CoV-2 infection: Identifying important knowledge gaps for investigation. date: 2021-11-10 journal: J Thorac Oncol DOI: 10.1016/j.jtho.2021.11.001 sha: 9e4afe976b06d510fa712b0ed123a333ba368b51 doc_id: 977682 cord_uid: mslceu1r Patients with lung cancer are especially vulnerable to COVID-19 with a >7-fold higher rate of becoming infected with SARS-CoV-2 COVID-19, a >3-fold higher hospitalization rate with high complication rates, and an estimated case fatality rate of over 30%. The reasons for the increased vulnerability are not known. In addition, beyond the pandemic’s direct impact on morbidity and mortality among patients with lung cancer, COVID-19, with its disruption of patient care, has also resulted in substantial impact on lung cancer screening and treatment/management. COVID-19 vaccines are safe and effective in people with lung cancer. Based on the available data, patients with lung cancer should continue their course of cancer treatment and get vaccinated against the SARS-CoV-2 virus. For unknown reasons, some patients with lung cancer mount poor antibody responses to vaccination. Thus, boost vaccination seems urgently indicated in this subgroup of vulnerable lung cancer patients. However, many unanswered questions regarding vaccination in this population remain, including the magnitude, quality, and duration of antibody response, and the role of innate and acquired cellular immunity for clinical protection. Additional important knowledge gaps also remain including: how can we best protect patients with lung cancer from developing COVID-19 including managing lung cancer patient care and the home environment of lung cancer patients; are there clinical/treatment demographics and tumor molecular demographics that impact severity of COVID-19 disease in lung cancer patients; does anticancer treatment impact antibody production and protection; does SARS-CoV-2 infection impact the development/progression of lung cancer; and are special measures and vaccine strategies need for patients with lung cancer as viral variants of concern emerge. vaccinated against the SARS-CoV-2 virus. For unknown reasons, some patients with lung cancer 50 mount poor antibody responses to vaccination. Thus, boost vaccination seems urgently indicated 51 in this subgroup of vulnerable lung cancer patients. However, many unanswered questions 52 regarding vaccination in this population remain, including the magnitude, quality, and duration 53 of antibody response, and the role of innate and acquired cellular immunity for clinical 54 protection. Additional important knowledge gaps also remain including: how can we best 55 protect patients with lung cancer from developing COVID-19 including managing lung cancer 56 patient care and the home environment of lung cancer patients; are there clinical/treatment 57 demographics and tumor molecular demographics that impact severity of COVID-19 disease in 58 lung cancer patients; does anticancer treatment impact antibody production and protection; does 59 SARS-CoV-2 infection impact the development/progression of lung cancer; and are special 60 measures and vaccine strategies need for patients with lung cancer as viral variants of concern 61 emerge. 62 63 Of the many disparities revealed by the COVID-19 (coronavirus disease 2019) pandemic, one of 66 immediate medical concern is the apparent increased incidence and severity of COVID-19 67 among cancer patients, 1 and in particular those with lung cancer ( Because SARS-CoV-2 infection of the lung results in COVID-19 associated pulmonary changes 132 (as for example, lung abnormalities on chest CT scans and changes in pulmonary function), 133 including potential changes in lung epithelial cells, we will also need to study if there is a 134 correlation between this infection and lung cancer onset on a population level. There is also a 135 concern that COVID- Given that Japan was among the best performing countries is controlling the pandemic it is Most studies so far have found no association between cancer therapy and increased mortality 215 among patients with cancer and COVID-19 ( association between PD-1 blockage treatment and COVID-19 severity once adjusting for 234 smoking history for 5 or more pack years. 6 These data are nearly all from unvaccinated patients. 235 Given increasing vaccination rates among patients with lung cancer, an important question today 236 is how vaccinated lung cancer patients will be affected by treatment approaches (see vaccine 237 section). 238 239 240 Global SARS-CoV-2 vaccinations are rapidly rolling out. Despite the significant burden on lung 244 cancer patients, the initial COVID-19 vaccine trials had few, if any, lung cancer patient enrolled. immune-related adverse events (irAEs) and systemic side effects. 55 The most common side 260 effects were mild (e.g., pain at the site of injection). These results suggest that administration of 261 SARS-CoV-2 mRNA vaccines is safe in patients with cancer, including those treated with 262 immunotherapy, similarly to other common vaccines, such as seasonal influenza. 57 Initial data suggests that SARS-CoV-2 vaccines are effective in patients with lung cancer (Table 265 3 was associated in a multivariate analysis with age and long-term corticosteroid treatment. 320 Interestingly, thirty patients with persistent low antibody titers received a third vaccine dose, 321 resulting in an 88% immunization rate. 62 These results support the use of a third dose for patients 322 J o u r n a l P r e -p r o o f with lack of immunization after complete two vaccine doses and could contribute to appropriate 323 seroprotection in patients still poorly immunized post-two vaccines. 324 325 326 2) variants of concern (VOCs) were recently 344 reported. The results of this study suggest that even a single dose of these 3 vaccines provide 345 good to excellent protection against symptomatic infection and severe outcomes caused by the 4 346 currently circulating VOCs, and that 2 doses are likely to provide even higher protection. 65 347 348 Another observational study conducted in Scotland confirmed that ChAdOx1 and BNT162b2 349 vaccines are effective in reducing the risk of SARS-CoV-2 infection and COVID-19 350 hospitalization in people with the Delta VOC, but these effects on infection appeared to be 351 diminished when compared to those with the Alpha VOC. 66 Further data, especially in cancer 352 patients, are urgently needed. Importantly, vaccine efficacy has been linked to anti-spike antibody titers both from a global 355 perspective across phase III efficacy trials 67-69 and recently also from an individual level. 70,71 The 356 establishment of a threshold antibody titer needed for protection will help to guide patient 357 management since serology tests are widely available and patients with low antibody responses 358 could then receive a booster dose. An absolute correlate of protection will also in general inform 359 policy-making regarding potential booster doses in non-responders or individuals with 360 suboptimal responses as seen in some lung cancer patients. As a first step to improve immunity 361 in those who do not respond well, the US CDC has recently recommended booster doses (a third 362 mRNA vaccine dose) for immunocompromised and immunosuppressed individuals. However, while most of the above studies do not specifically apply to lung cancer population(s), 365 many questions have to be answered for this particular patient group. At Mt. Sinai in New York, 366 a Center of Excellence for COVID-19 serological studies was established through an 367 NCI/SeroNet U-54 grant and in collaboration with UT Southwestern and University of Colorado. 368 The center is conducting a large prospective match-controlled study of patients with lung cancer 369 evaluating their antibody and cellular immune response following SARS-CoV-2 vaccination. 370 Initial findings confirm that most patients with lung cancer mount a good response to 371 vaccination. 72 However, a subgroup of patients did not mount "adequate" antibody response. 372 The goals of the study are to study magnitude, quality, and duration of neutralizing antibody 373 response after SARS-CoV-2 infection or vaccination and correlated to cellular immunity in a 374 long-term follow-up program. future practice? As it appears that we will be dealing with COVID-19 (and a variety of viral 432 variants of concern) for the foreseeable future, both continued collection of retrospective data, 433 and planning for prospective studies of mitigation measures taken during COVID 19 pandemic, 434 and clinical pathologic/molecular correlative studies for SARS-CoV-2 infection and 435 development of COVID-19 in patients with lung cancer appear essential to help fill in our 436 current knowledge gaps. important to perform studies specific to lung cancer. While it is encouraging that the initial 445 available data suggest that COVID-19 vaccines seem to be protective in most patients with lung 446 cancer, further research is needed to understand the mechanisms underlying SARS-CoV-2 447 infection, COVID-19 vaccination, and immunity in lung cancer patients to better protect and care 448 for this vulnerable population. Furthermore, while new virus variants are emerging, there will be 449 an ongoing need to continue such studies to understand factors that contribute to clinical 450 protection of patients with lung cancer. Are some subgroups more vulnerable than others and 451 what is the impact of antineoplastic therapies? Further studies on vaccination in lung cancer 452 patients are needed to determine the role of booster-vaccination, and to determine the optimal 453 vaccination programs. The duration of immunological protection is another key factor that will 454 impact on long-term care of lung cancer patients. To evaluate anti-viral immune protection, it is 455 likely that routine serological monitoring for anti-viral antibody and potential anti-viral T cell 456 activity will be required. Likewise, detailed studies on the relationship between vaccination and 457 the efficacy/toxicity of individual cancer therapies is paramount. Finally, as we consider the 458 critical role that immunogenicity plays in lung cancer pathogenesis and treatment, it is highly 459 likely that fundamental questions surrounding the intersection of COVID-19 and cancer will lead 460 to discoveries and breakthroughs that will positively impact future lung cancer treatment and 461 prevention strategies. Acknowledgements 464 Work in the Krammer laboratory on SARS-CoV-2 is supported by the NIAID Collaborative J o u r n a l P r e -p r o o f Hallmarks of cancer: the next generation The basics of epithelial-mesenchymal transition Microenvironmental regulation of metastasis Transitions between epithelial and mesenchymal states: 604 acquisition of malignant and stem cell traits Pulmonary fibrosis secondary to COVID-606 19: a narrative review Risk factors and clinical 609 characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort 610 study Impact of the COVID-19 Pandemic on Cancer 612 Care: A Global Collaborative Study Impact of the COVID-19 Pandemic on 615 Lung Cancer Screening Program and Subsequent Lung Cancer Management of Lung Nodules and Lung 618 Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Radiol 619 Imaging Cancer Impact of the COVID-19 Pandemic on Cancer 621 Clinical Trials 03 -The Impact of the COVID-19 Pandemic on Lung Cancer 624 Screening Programs in the United States Lung Cancer Screening Rates 626 During the COVID-19 Pandemic Changes in the Number of US Patients With 629 Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) 630 Pandemic Association of Cancer Screening Deficit 633 in the United States With the COVID-19 Pandemic Collateral effects of the coronavirus disease 2019 636 pandemic on lung cancer diagnosis in Korea 35P Lung cancer diagnosis and continuum of 638 care: How did the COVID-19 outbreak impact? Data from an Italian multicenter study Effect of 641 COVID-19 on Thoracic Oncology Surgery in Spain: A Spanish Thoracic Surgery Society 642 (SECT) Survey. Cancers (Basel) Challenges in 644 Management of Patients With Lung Cancer in Times of COVID-19: An Imaging 645 Perspective COVID-19 and early-stage lung cancer both featuring 647 ground-glass opacities: a propensity score-matched study Coronavirus Disease 2019 or Lung Cancer: 650 A Differential Diagnostic Experience and Management Model From Wuhan The impact of COVID-19 on systemic 653 anticancer treatment delivery in Scotland The effect of clinical 656 decision making for initiation of systemic anticancer treatments in response to the 657 COVID-19 pandemic in England: a retrospective analysis Incidental diagnosis of lung adenocarcinoma 660 following coronavirus OC 43 severe pneumonia. Monaldi Arch Chest Dis Inequalities in the decline and 663 recovery of pathological cancer diagnoses during the first six months of the COVID-19 664 pandemic: a population-based study Impact of COVID-19 pandemic on 667 lung cancer treatment scheduling Blockade on Severity of COVID-19 in Patients with Lung Cancers Association of clinical factors and recent 673 anticancer therapy with COVID-19 severity among patients with cancer: a report from 674 the COVID-19 and Cancer Consortium Clinical impact of COVID-19 on patients 677 with cancer (CCC19): a cohort study COVID-19 prevalence and mortality in patients 679 with cancer and the effect of primary tumour subtype and patient demographics: a 680 prospective cohort study Clinical portrait of the SARS-CoV-2 683 epidemic in European cancer patients Safety and Efficacy of the BNT162b2 mRNA 686 Covid-19 Vaccine Challenges and Opportunities for 689 COVID-19 Vaccines in Patients with Cancer Efficacy and Safety of the mRNA-1273 SARS-691 Serologic Status and Toxic Effects of the 693 SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer Evaluation of Seropositivity Following 696 BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing 697 Treatment for Cancer Seroconversion rates following 700 COVID-19 vaccination amongst patients with cancer. Cancer Cell Immunogenicity of SARS-CoV-2 messenger RNA 703 Vaccines in Patients with Cancer Current perspectives for SARS-CoV-2 705 vaccination efficacy improvement in patients with active treatment against cancer Safety and immunogenicity of one versus two 708 doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a 709 prospective observational study Short-term safety of the 712 BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune 713 checkpoint inhibitors Concomitant medications during immune checkpoint 717 blockage in cancer patients: Novel insights in this emerging clinical scenario Durability of Response to 720 SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment Six Month Efficacy and Toxicity Profile of 723 BNT162b2 Vaccine in Cancer Patients with Solid Tumors. Cancer Discov Immune responses to two and three doses of the 726 BNT162b2 mRNA vaccine in adults with solid tumors Efficacy of SARS-CoV-2 vaccine in thoracic 732 cancer patients: a prospective study supporting a third dose in patients with minimal 733 serologic response after two vaccine doses. medRxiv Effectiveness of Covid-19 Vaccines against 736 the B.1.617.2 (Delta) Variant SARS-CoV-2 Delta VOC in Scotland: 743 demographics, risk of hospital admission, and vaccine effectiveness A correlate of protection for SARS-CoV-2 vaccines is urgently needed Neutralizing antibody levels are highly 748 predictive of immune protection from symptomatic SARS-CoV-2 infection Evidence for antibody as a protective 751 correlate for COVID-19 vaccines Immune Correlates Analysis of the 754 mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv Covid-19 Breakthrough Infections in Vaccinated 757 Health Care Workers 01 -Analysis of Lung Cancer Patients Receiving SARS-CoV-2 760 Vaccines Revealed a Minority Subset With Poor Antibody Responses Relative to 761 Controls 09 -International Association for the Study of Lung Cancer 763 (IASLC) Study of the Impacts of COVID-19 on International Lung Cancer Clinical 764 Trials Early Impact of COVID-19 on the Conduct 766 of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings 767 From an Association of the Coronavirus 770 Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials American Society of Clinical Oncology Road to 773 Recovery Report: Learning From the COVID-19 Experience to Improve Clinical 774 Research and Cancer Care Utilization of COVID-19 Treatments and 778 Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium 779 (CCC19) Cohort Study Case Fatality Rate of Cancer Patients with COVID-782 19 in a New York Hospital System Does SARS CoV-2 infect lung cancer cells and is this infection important in the pathogenesis of COVID-29 disease? 2. Does SARS-CoV-2 infection of the lung in otherwise healthy individuals impact on the future development of lung cancer? 3. Does COVID-19 pulmonary disease impact the clinical behavior of lung cancer in individual patients? 4. Do patients with lung cancer develop inferior immune responses to SARS CoV-2 natural infection or vaccination? 5. Do clinical characteristics and therapy of lung cancer impact development and severity of COVID-19 and anti-SARS-CoV-2 immune responses? 6. How can we improve anti Summary of select studies exploring the impact of cancer treatments on COVID-19 severity